Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Afecta Pharmaceuticals

Org chart

Teams

Offices